F W Wit

Summary

Affiliation: Academic Medical Center
Country: The Netherlands

Publications

  1. ncbi request reprint CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients
    Ferdinand W N M Wit
    Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, National AIDS Therapy Evaluation Centre, 1105 AZ Amsterdam, The Netherlands
    J Infect Dis 186:1726-32. 2002
  2. ncbi request reprint Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons
    F W Wit
    National AIDS Therapy Evaluation Center NATEC, Department of Infectious Diseases, Tropical Medicine, and AIDS, Division of Internal Medicine, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands
    J Infect Dis 179:790-8. 1999
  3. doi request reprint Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study
    Ferdinand W N M Wit
    Center for Poverty related Communicable Diseases, and Department of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Clin Infect Dis 46:933-40. 2008
  4. ncbi request reprint Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy
    Ferdinand W N M Wit
    National AIDS Therapy Evaluation Center, Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, The Netherlands
    J Infect Dis 186:23-31. 2002
  5. ncbi request reprint Experience with nevirapine in previously treated HIV-1-infected individuals
    F W Wit
    National AIDS Therapy Evaluation Centre, Department of Internal Medicine, University of Amsterdam, The Netherlands
    Antivir Ther 5:257-66. 2000
  6. ncbi request reprint Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection
    M van der Valk
    International Antiviral Therapy Evaluation Center, Academic Medical Center, Amsterdam, The Netherlands
    AIDS 15:847-55. 2001
  7. ncbi request reprint Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy
    F Van Leth
    International Antiviral Therapy Evaluation Center, Department of Internal Medicine, Academic Medical Center, University of Amsterdam, 1005 Amsterdam, The Netherlands
    AIDS Res Hum Retroviruses 22:232-9. 2006
  8. ncbi request reprint Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study
    F van Leth
    International Antiviral Therapy Evaluation Center, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
    Lancet 363:1253-63. 2004
  9. ncbi request reprint Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine
    F W Wit
    International Antiviral Therapy Evaluation Center, Department of Human Retrovirology and Department of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
    AIDS 15:2423-9. 2001
  10. ncbi request reprint Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients
    K Pogany
    Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine, and AIDS, National AIDS Trial and Evaluation Center NATEC, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands
    AIDS Res Hum Retroviruses 21:922-6. 2005

Collaborators

Detail Information

Publications20

  1. ncbi request reprint CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients
    Ferdinand W N M Wit
    Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, National AIDS Therapy Evaluation Centre, 1105 AZ Amsterdam, The Netherlands
    J Infect Dis 186:1726-32. 2002
    ....
  2. ncbi request reprint Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons
    F W Wit
    National AIDS Therapy Evaluation Center NATEC, Department of Infectious Diseases, Tropical Medicine, and AIDS, Division of Internal Medicine, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands
    J Infect Dis 179:790-8. 1999
    ..This was significantly more frequent for regimens containing saquinavir (62%; 27% for virologic failure) or ritonavir (64%; 55% for intolerance) as single protease inhibitor...
  3. doi request reprint Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study
    Ferdinand W N M Wit
    Center for Poverty related Communicable Diseases, and Department of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Clin Infect Dis 46:933-40. 2008
    ..It is unclear whether these guidelines also apply to treatment-experienced patients switching to NVP-based combination therapy...
  4. ncbi request reprint Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy
    Ferdinand W N M Wit
    National AIDS Therapy Evaluation Center, Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, The Netherlands
    J Infect Dis 186:23-31. 2002
    ..In 97% of cases, >or=1 risk factor was present. In HBV-coinfected patients using 3TC, continued use of 3TC should be considered, even if 3TC-resistant HIV strains develop...
  5. ncbi request reprint Experience with nevirapine in previously treated HIV-1-infected individuals
    F W Wit
    National AIDS Therapy Evaluation Centre, Department of Internal Medicine, University of Amsterdam, The Netherlands
    Antivir Ther 5:257-66. 2000
    ..To assess the tolerability, virological, immunological and clinical effects of nevirapine in the setting of a compassionate use programme in pretreated HIV-infected individuals...
  6. ncbi request reprint Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection
    M van der Valk
    International Antiviral Therapy Evaluation Center, Academic Medical Center, Amsterdam, The Netherlands
    AIDS 15:847-55. 2001
    ..The low incidence of lipodystrophy in patients with no or limited NRTI exposure supports further evaluation of NRTI-sparing regimens as alternatives to current antiretroviral regimens...
  7. ncbi request reprint Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy
    F Van Leth
    International Antiviral Therapy Evaluation Center, Department of Internal Medicine, Academic Medical Center, University of Amsterdam, 1005 Amsterdam, The Netherlands
    AIDS Res Hum Retroviruses 22:232-9. 2006
    ....
  8. ncbi request reprint Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study
    F van Leth
    International Antiviral Therapy Evaluation Center, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
    Lancet 363:1253-63. 2004
    ..The 2NN Study was a randomised comparison of the non-nucleoside reverse-transcriptase inhibitors (NNRTI) nevirapine and efavirenz...
  9. ncbi request reprint Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine
    F W Wit
    International Antiviral Therapy Evaluation Center, Department of Human Retrovirology and Department of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
    AIDS 15:2423-9. 2001
    ..Short-term therapy with prednisolone did not prevent HSR in patients using ABC with or without NVP...
  10. ncbi request reprint Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients
    K Pogany
    Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine, and AIDS, National AIDS Trial and Evaluation Center NATEC, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands
    AIDS Res Hum Retroviruses 21:922-6. 2005
    ..Our results illustrate that occult HBV infection is more a diagnostic than a clinical problem. It may be caused by very low levels of HBV replication, concurrent presence of HBsAg and anti-HBs, or mutations in the HBsAg a determinant...
  11. ncbi request reprint Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients
    Reshma Saskia Autar
    HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Thai Red Cross Aids Research Centre TRCARC, 104 Rajdumri Road, 10330 Pathumwan, Bangkok, Thailand
    AIDS 21:1535-9. 2007
    ..However, toxicity, storage conditions and high costs of antiretroviral treatment may necessitate interruption of ritonavir. Ketoconazole was investigated as a potential booster of once-daily (o.d.) saquinavir...
  12. ncbi request reprint Efavirenz: a review
    Saskia M E Vrouenraets
    IATEC, Pietersbergweg 9, 1105 BM Amsterdam, The Netherlands
    Expert Opin Pharmacother 8:851-71. 2007
    ..This review outlines important and recent pharmacological and clinical data, which explain why efavirenz became a component of preferred treatment regimens today...
  13. ncbi request reprint Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries
    Papa S Sow
    Centre Hospitalier Universitaire de Fann, Dakar, Senegal
    J Acquir Immune Defic Syndr 44:262-7. 2007
    ..HIV-1 screening, therapy, counseling, monitoring, training, and education were provided free of charge...
  14. ncbi request reprint A phase I/IIa study with succinylated human serum albumin (Suc-HSA), a candidate HIV-1 fusion inhibitor
    Joost N Vermeulen
    IATEC, Amsterdam, The Netherlands
    Antivir Ther 12:273-8. 2007
    ..5-5.0 microg/ml). Suc-HSA was safe in rats and monkeys, and showed antiretroviral effect in a human-to-mouse model. We evaluated safety and pharmacokinetics of single and multiple doses of Suc-HSA in HIV-1-infected individuals...
  15. ncbi request reprint Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis
    Reshma S Autar
    The HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Center, Bangkok, Thailand
    Antivir Ther 10:937-43. 2005
    ..However, limited data are available about whether or not nevirapine and rifampin can be safely coadministered without the plasma concentration of nevirapine falling below therapeutic levels...
  16. ncbi request reprint Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy
    Rieneke M E van Praag
    National AIDS Therapy Evaluation Center NATEC, Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, University of Amsterdam, The Netherlands
    AIDS 16:719-25. 2002
    ..In a large percentage of such patients, more sensitive assays provide evidence of residual viral replication. The question is whether more potent therapy can further suppress this residual replication...
  17. ncbi request reprint Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients
    Reshma Saskia Autar
    The HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, 104 Rajdumri Road, 10330 Pathumwan, Bangkok, Thailand
    J Antimicrob Chemother 56:908-13. 2005
    ..Differential exposure to saquinavir/ritonavir may lead to therapy failure. The objective was to identify factors that influence variability of saquinavir/ritonavir plasma concentrations...
  18. ncbi request reprint Nelfinavir plasma concentrations are low during pregnancy
    Jeannine F J B Nellen
    Academic Medical Center, Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine, and AIDS, Amsterdam, The Netherlands
    Clin Infect Dis 39:736-40. 2004
    ..After we adjusted for confounders, we found that the mean nelfinavir CR was 34% lower in pregnant women (P=.02). With targeted interventions, subsequent CRs in pregnant women showed a significant increase (median increase, 0.31; P=.01)...
  19. ncbi request reprint Discordant responses during antiretroviral therapy: role of immune activation and T cell redistribution rather than true CD4 T cell loss
    Mette D Hazenberg
    Department of Clinical Viro Immunology, Sanquin Research, CLB and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, The Netherlands
    AIDS 16:1287-9. 2002
    ..Low reactivity to rebounding virus may preserve normal T lymphocyte distribution over blood and tissues and be associated with stable peripheral blood T cell numbers in virological failures to HAART...
  20. ncbi request reprint Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy
    Frank van Leth
    International Antiviral Therapy Evaluation Center, Department of Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
    J Acquir Immune Defic Syndr 38:296-300. 2005
    ..We compared the rate of pVL decline in patients starting ART with nevirapine (NVP), efavirenz (EFV), or both drugs combined in addition to lamivudine (3TC) and stavudine (d4T)...